The between Now and Then of Lung Cancer Chemotherapy and Immunotherapy

International Journal of Molecular Sciences

Angela Celetti¹  Francesco Morra¹  Roberta Visconti¹  Gianluca Guggino² 

[1] Institute for the Experimental Endocrinology and Oncology “G. Salvatore”, Italian National Council of Research, via S. Pansini 5, 80131 Napoli, Italy;Thoracic Surgery Unit, Antonio Cardarelli Hospital, via A. Cardarelli 9, 80131 Napoli, Italy;

关键词: lung neoplasms;    antineoplastic agents;    biomarkers;    poly(ADP-ribose) polymerase inhibitors;    CCDC6;   

DOI  :  10.3390/ijms18071374

来源: DOAJ

【 摘 要 】

Lung cancer is the most common cancer worldwide. Disappointingly, despite great effort in encouraging screening or, at least, a close surveillance of high-risk individuals, most of lung cancers are diagnosed when already surgically unresectable because of local advancement or metastasis. In these cases, the treatment of choice is chemotherapy, alone or in combination with radiotherapy. Here, we will briefly review the most successful and recent advances in the identification of novel lung cancer genetic lesions and in the development of new drugs specifically targeting them. However, lung cancer is still the leading cause of cancer-related mortality also because, despite impressive initial responses, the patients often develop resistance to novel target therapies after a few months of treatment. Thus, it is literally vital to continue the search for new therapeutic options. So, here, on the basis of our recent findings on the role of the tumor suppressor CCDC6 protein in lung tumorigenesis, we will also discuss novel therapeutic approaches we envision for lung cancer.

【 授权许可】

Unknown